Date: October 04, 2023
John Mascarenhas, MD, stands as a distinguished authority in the realm of myelofibrosis treatment. Drawing upon his extensive expertise and experience, Dr. Mascarenhas delivered an enlightening presentation in 2023, shedding light on the drugs Pacritinib and Mamelotnib. During his presentation, he underscored the critical importance of comprehending the distinct properties and profiles of these two JAK inhibitors.
With eloquence, Dr. Mascarenhas elucidated Pacritinib’s unique characteristics, such as its sparing of JAK1 and its robust ACVR1 inhibition, while also delving into emerging data regarding its impact on immune responses. In contrast, he portrayed Mamelotnib as an equipotent JAK1 and JAK2 inhibitor, devoid of ACVR1 activity. Dr. Mascarenhas, engaging the audience actively, presented a challenging case study—a newly diagnosed primary myelofibrosis patient with a myriad of clinical factors. He encouraged the audience to participate in a stimulating exercise, prompting them to choose between Pacritinib and Mamelotnib for this specific case. This exercise sparked insightful discussions and considerations among the attendees.
With a laser focus on addressing thrombocytopenia, Dr. John Mascarenhas underscored the utmost importance of tailoring treatment selections to the unique needs of individual patients in the ever-evolving landscape of myelofibrosis management. His exceptional expertise and remarkable ability to captivate the audience left an indelible mark on all those fortunate enough to be in attendance.